Recombinant tissue plasminogen activator (rtPA) and stroke unit for acute ischaemic stroke in developing countries, are they cost-effective?

Int J Stroke. 2012 Oct;7(7):E9. doi: 10.1111/j.1747-4949.2012.00892.x.
No abstract available

Publication types

  • Letter

MeSH terms

  • Cost-Benefit Analysis / economics
  • Developing Countries / economics*
  • Hospital Departments / economics
  • Humans
  • Recombinant Proteins / economics
  • Recombinant Proteins / therapeutic use
  • Stroke / drug therapy
  • Stroke / economics*
  • Stroke / epidemiology
  • Tissue Plasminogen Activator / economics*
  • Tissue Plasminogen Activator / therapeutic use

Substances

  • Recombinant Proteins
  • Tissue Plasminogen Activator